86P The predictive values of EPHA3 mutations for response to immune checkpoint inhibitors in solid tumors

Abstract

Ephrin type-A receptors (EPHA) are members of the EPH family of receptor tyrosine kinases (RTKs) with nine EPHA receptors (EPHA1-8, EPHA10). Previous studies demonstrated that EPHA5 and EPHA7 mutations could predict the clinical benefit of immune checkpoint inhibitors (ICIs). We herein investigated the associations of EPHA3 mutations with tumor mutation burden (TMB), PD-L1 expression, microsatellite instability-high (MSI-H), tumor-infiltrating lymphocytes (TILs), and clinical response to ICIs. This will be very helpful for identifying patients who may benefit from immunotherapy.